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Both the Human papillomavirus (HPV) major (L1) and minor (L2) capsid proteins have been well investi-
gated as potential vaccine candidates. The L1 protein first oligomerizes into pentamers, and these capsomers
assemble into virus-like particles (VLPs) that are highly immunogenic. Here we examine the potential of using
HPV type 16 (HPV-16) L1 subunits to display a well-characterized HPV-16 L2 epitope (LVEETSFIDAGAP),
which is a common-neutralizing epitope for HPV types 6 and 16, in various regions of the L1 structure. The L2
sequence was introduced by PCR (by replacing 13 codons) into sequences coding for L1 surface loops D-E
(ChiC-L2), E-F (ChiA-L2), and an internal loop C-D (ChiH-L2); into the h4 helix (ChiF-L2); and
between h4 and -J structural regions (ChiE-L2). The chimeric protein product was characterized using a
panel of monoclonal antibodies (MAbs) that bind to conformational and linear epitopes, as well as a polyclonal
antiserum raised to the L2 epitope. All five chimeras reacted with the L2 serum. ChiA-L2, ChiE-L2, and
ChiF-L2 reacted with all the L1 antibodies, ChiC-L2 did not bind H16:V5 and H16:E70, and ChiH-L2 did
not bind any conformation-dependent MAb. The chimeric particles elicited high-titer anti-L1 immune re-
sponses in BALB/c mice. Of the five chimeras tested only ChiH-L2 did not elicit an L2 response, while
ChiF-L2 elicited the highest L2 response. This study provides support for the use of PV particles as vectors
to deliver various epitopes in a number of locations internal to the L1 protein and for the potential of using
chimeric PV particles as multivalent vaccines. Moreover, it contributes to knowledge of the structure of HPV-16
L1 VLPs and their derivatives.
Papillomaviruses (PVs) belong to the taxonomic family Pap-
illomaviridae and have a double-stranded circular DNA ge-
nome with a typical size of8 kb (36). PVs have nonenveloped
isometric virions 55 nm in diameter. The viral capsid contains
major (L1) and minor (L2) capsid proteins at a molar ratio of
30 to 1, with 360 L1 molecules arranged as 72 pentamers or
capsomers, in a T  7d lattice (44). L2 proteins are presumed
to associate with the penton vertices of the capsomers. Some
human PV (HPV) types infecting the mucosal epithelium
(such as HPV type 6 [HPV-6] and HPV-11) cause benign
condylomas, but a large number of types (HPV-16, -18, -33,
-35, -39, -45, -52, -58, and -59, among others) can cause cervical
cancer. Of these high-risk types, HPV-16 is the most prevalent,
found in approximately 50% of cases (44).
In recent years there has been tremendous progress in the
development of prophylactic vaccines for HPV types that cause
genital infections. PV virus-like particles (VLPs), made either
from expression of the capsid genes L1 alone or by coexpres-
sion of L1 and L2, have been proven to induce protective
immunity in animal models (1, 8, 13, 20, 38, 39) and are
currently in clinical trials for the prevention of HPV infections
(12, 29, 35, 43).
Numerous serological studies have shown that there is a
strong immune response to the L1 protein in humans after
infection with genital HPV types. The response is long-term
but type specific (2, 3, 20, 40). Most of the neutralizing epitopes
previously identified are nonlinear and conformation depen-
dent, and their surface location and amino acid composition
have been partially characterized by monoclonal antibody
(MAb) binding and immunization studies. In HPV-16, the L1
residues 50, 266, and 282 are considered to be vital for the
binding of the neutralizing MAbs H16:V5 and H16:E70 (41).
Linear epitopes that are identified by MAbs H16:J4 (amino
acids [aa] 261 to 280) and H16:I23 (aa 111 to 130) show weak
cross-neutralizing activity for HPV-18, -31, -33, -45, -55, and
-59 in addition to HPV-16 (9).
There are a number of studies describing the use of PV
VLPs to deliver and/or display foreign epitopes (11, 22, 23, 25,
27, 37). L1 C-terminal fusion chimeras have worked well in
presenting the epitopes of the HPV-16 E7 protein (15, 25),
human immunodeficiency virus type 1 (HIV-1) p18 cytotoxic T
lymphocyte epitopes, and HIV-1 gp120 (22, 23) and HIV-1
gp41 epitopes (37), in HPV-11, HPV-16, and bovine PV-1.
Attempts have been made to insert epitopes into the core
sequences of the PV L1, with the result of capsomers rather
than VLPs being formed (37). There are convincing data in the
literature to indicate that capsomers are significantly immuno-
genic and in fact capable of eliciting a neutralizing immune
response (10, 31, 42).
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A common-neutralizing epitope for HPV-6 and -16 is pres-
ent between aa 108 and 120 (LVEETSFIDAGAP) of the HPV-
16 minor capsid protein, L2 (17). Sera of mice immunized with
this peptide cross-reacted with L1/L2 capsids of HPV-6, -11,
and -18 (16–18). Preincubation of monkey COS-1 cells with the
synthetic L2 epitope reduces the susceptibility of COS-1 cells
to infection with HPV-16 L1/L2 pseudovirions (19).
Based on the reports of cross-reactivity of the neutralizing
L2 epitope characterized by Kawana et al. (16–19) and the evi-
dence that VLPs can be used to deliver foreign epitopes (14,
15, 22, 23, 25, 26, 28, 32, 34, 37), we decided to investigate the
possibility of making chimeric vaccine candidates with the L2
epitope displayed on HPV-16 L1 particles, which hopefully
maintained the neutralizing MAb H16:V5 and H16:E70-bind-
ing epitopes. We constructed five HPV-16 L1 chimeras that
displayed the L2 epitope as replacement sequences, expressed
them in insect cells using a baculovirus expression system, and
characterized the chimeric products with a panel of MAbs.
This study opens various avenues for multivalent vaccine de-
velopment using PV particles.
MATERIALS AND METHODS
Synthesis of chimeric constructs and expression in insect cells by recombinant
baculovirus. Chimeric constructs were prepared by PCR mutagenesis of the 39
bp regions to be replaced, with the primers being designed with the 3 end coding
for the L2 peptide (Table 1). The HPV-16 L1 gene (South African isolate;
GenBank accession no. AY177679) cloned in the pSK plasmid vector (Strat-
agene Cloning Systems) was used as a template. The mutagenesis was carried out
using a two-step PCR system. First, a chimeric template was generated using the
Expand Long Template PCR System (Roche) that is suited for the accurate
amplification of large DNA templates. The PCR mixture (50 l) was digested
with DpnI restriction endonuclease (to digest methylated template DNA); 5 l of
this was used in the second step using Pfu DNA polymerase (Promega). DH5
Escherichia coli competent cells were transformed with the amplified DNA and
the chimeric product was sequenced.
The L1 chimeric constructs were expressed in insect cells using the Bac-to-Bac
baculovirus expression system (Life Technologies). The chimeras were cloned
into pFastbac1 vector (SalI/XbaI restriction sites). The DNA from these clones
was used to transfect DH10bac E. coli cells to prepare bacmid clones. The
bacmid DNA was transfected into sf21 insect cells using Cellfectin (Life Tech-
nologies). The basic Bac-to-Bac protocol was followed to amplify the recombi-
nant virus and to infect the sf21insect cells for expression of the chimeric VLPs.
Preparation of chimeric HPV-16 L1 particles. The infected insect cells were
spun down at 1,000  g, resuspended in high-salt phosphate-buffered saline
(PBS) (0.5 M NaCl) and sonicated four times at 5-s intervals. The sonicated
material was overlaid onto a 40% sucrose cushion and pelleted at 100,000 g for
3 h. The pellet was resuspended in CsCl buffer (PBS with 0.4g/ml CsCl) with
sonication (four times at 5-s intervals). The suspension was centrifuged at
100,000  g at 10°C for 24 h in a Beckman SW50.1 rotor. Fractions (500 l) were
collected and analyzed by indirect enzyme-linked immunosorbent assay (ELISA)
using MAb H16:J4 (binds linear epitope 261 to 280) (7). Fractions that bound
MAb H16:J4 were pooled and dialyzed against PBS at 4°C overnight.
Expression and purification of HPV-16 L2 protein in E. coli. The HPV-16 L2
gene was amplified by PCR from an HPV-16 L2-E2-E7 construct (provided by
J. Schiller, National Institutes of Health) and cloned into the pProEx HT Pro-
karyotic Expression Vector (Life Technologies). Competent DH5 E coli cells
were transformed and protein expression was induced as per manufacturer’s
recommendations. The induced cells were pelleted and lysed (50 mM Tris-HCl
[pH 8.5], 5 mM 2-mecaptoethanol, 1 mM phenylmethylsulfonyl fluoride, lyso-
zyme [10 g/l]) on ice for half an hour. Triton X-100 (1% final concentration)
was added and incubated at 37°C; the nucleic acid was digested using 5 l of
DNase I (1 mg/ml) and 5 l of RNase A (10 mg/ml) per 1 ml of lysis mix at room
temperature for 30 min. The L2 protein (insoluble) was pelleted at 12,000 g for
5 min and resuspended in a buffer containing 50 mM Tris-HCl (pH 8.0), 5 mM
2-mercaptoethanol, 10 mM EDTA (pH 8.0), and 0.5% Triton X-100 buffer. The
L2 protein was pelleted at 12,000  g and resuspended in PBS.
Western blot analysis of the chimeric protein product. The chimeric protein
was denatured for 10 min at 100°C in sodium dodecyl sulfate (SDS) disruption
solution. The denatured chimeric protein was resolved on an SDS–10% poly-
acrylamide gel. The resolved gel was transferred onto nitrocellulose membrane
by semidry electrophoresis (Bio-Rad) for 25 min at 25 V. The membrane was
blocked using 1% nonfat milk for 2 h and incubated with primary antibody at a
dilution of 1:1,000 overnight at 4°C. The membrane was washed with PBS–0.05%
Tween 20 and probed, with alkaline phosphatase-labeled secondary antibody
diluted 1:2,000, for 1 h at room temperature. Reaction was detected colorimetri-
cally using 5-bromo-4-chloro-3-indoyl-phosphate (BCIP) and 4-nitro blue tetra-
zolium chloride (NBT) substrates.
Antibody characterization of chimeric particles by ELISA. A dilution series of
each of the chimeric protein products was tested against MAb H16:J4, and di-
lutions that gave similar absorbances by ELISA were selected in order to nor-
malize the antigen concentrations. The normalized dilutions were used for fur-
ther antibody characterization by ELISA. ELISA plates were coated with the
chimeric protein at the appropriate dilution, and the plates were stored overnight
at 4°C. The plates were washed four times with PBS and blocked with 1% nonfat
milk. The MAbs and polyclonal antibodies were diluted at 1:500 in PBS-milk and
allowed to bind to the chimeric proteins for 2 h at room temperature, and this
was followed by four stringent washes. The bound primary antibody was probed
with the relevant alkaline phosphatase-labeled secondary antibody (goat anti-
rabbit and goat anti-mouse). The binding was detected using p-nitrophenyl
phosphate (Sigma), and the absorbances on the ELISA plate were read at 405 nm.
Transmission electron microscopy of chimeric particles. The chimeric parti-
cles were viewed either after direct adsorption onto carbon-coated copper grids
or after immunotrapping with preadsorbed H16:J4 MAb (binds L1 linear epitope
from aa 261 to 280) at a dilution of 1:50. The grids were stained with 2% uranyl
acetate and viewed using a JEOL 200CX transmission electron microscope.
Immunization of mice with chimeric protein particles. Six groups of five mice
were used for this study. The 8-week-old female BALB/c mice were immunized
with chimeric protein (100 g) at three subcutaneous sites with Freund’s incom-
plete adjuvant (1:1). The immunizations were done at 0, 2, and 4 weeks, and the
serum samples (200 l) were collected at weeks 0 (preimmunization), 1, 3, and 5.
Serum analysis for immune response to HPV-16 L1. ELISA plates were
coated overnight at 4°C with 100 l of baculovirus-produced native HPV-16 L1
VLPs at a concentration of 1 g/ml. The plates were washed three times with
PBS, blocked with 1% nonfat milk (300 l) in PBS, and incubated at room
temperature for 2 h. After washing, the ELISA plates were probed with serum
(100 l) diluted in 1% nonfat milk and incubated for 2 h. Anti-mouse–horse-
radish peroxidase conjugate (DAKO) (100 l diluted 1:2,000 in 1% nonfat milk)
was added to the ELISA plates after washing four times with PBS. The plates
were incubated for an hour at 37°C and washed four times with PBS. 3,3,5,5-
tetramethyl-benzidine substrate (100 l per well) (TMB Microwell Peroxidase
Substrate System; Kirkegaard & Perry Laboratories) was added, and plates al-
lowed to react in the dark for 15 min. The reaction was stopped with the addition
of 100 l of 0.5 M H2SO4/well, and the optical density was read at 450 nm.
Serum analysis for immune response to HPV-16 L2 protein. The L2 protein
was denatured for 10 min at 100°C in SDS disruption solution and resolved on
an SDS–10% polyacrylamide gel. The resolved gel was transferred onto nitro-
cellulose membrane by semidry electrophoresis (Bio-Rad) for 45min at 17 V.
The membrane was blocked using 1% nonfat milk protein for 2 h and incubated
overnight at 4°C with L2 polyclonal antibody (against the L2 peptide spanning aa
108 to 120) at a dilution of 1:1,000 for the positive control, and 1:100 for the
mouse sera, to detect L2 epitope immune response. The membrane was washed
with PBS/Tween and probed with alkaline phosphatase-labeled secondary anti-
body at 1:5,000 for 1 h at room temperature. This was detected by a colorimetric
reaction using NBT and BCIP.
RESULTS
Synthesis and expression of chimeric constructs. Five re-
gions of the L1 structure identified as having potential for
displaying the L2 epitope were selected for this study (Table
1). The neutralizing L2 epitope sequence was introduced by a
PCR-based strategy, involving replacing 13 codons in the L1
gene sequences coding for surface loops D-E (ChiC-L2) and
E-F (ChiA-L2), an internal loop C-D (ChiH-L2), the h4
helix (ChiF-L2), and the region between the h4 helix and the
	-J sheet (ChiE-L2) (Table 1). The C-D loop is not surface
exposed in VLPs and would only putatively be exposed in
pentameric capsomers. Multiple sequence alignment indicates
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that the C-D loop and the h4 helix are highly conserved be-
tween PV types. Secondary structure prediction data indicated
that the h4 helix would be destroyed by substitution of the L2
epitope into this region. In brief, the L2 sequence in ChiA-L2
is probably displayed on the outer rim of the pentamer head,
ChiC-L2 on the pentamer head, ChiE-L2 and ChiF-L2 on
the C-terminal arm, and ChiH-L2 on an internal loop at the
base of the pentamer.
The chimeric constructs were successfully expressed in insect
cells using recombinant baculoviruses and purified using CsCl
gradient centrifugation. Fractions were analyzed by ELISA
using H16:J4 MAb, since the epitope that binds this MAb was
not altered in any construct. Positive fractions were pooled and
dialyzed for further analysis. The sizes of the chimeric L1-L2
protein products, predicted as 55 kDa, were confirmed by
Western blot analysis using H16:J4 MAb (Fig. 1).
Transmission electron microscopy of chimeric particles.
Chimeric particles from ChiC-L2 and ChiE-L2 formed rec-
ognizable VLPs and capsomers, whereas the rest of the chi-
meras apparently only formed capsomers and amorphous ag-
gregates (Fig. 2).
Antibody characterization of the chimeric L1 protein prod-
ucts using a panel of MAbs. The ELISA binding results for
purified chimeric proteins with a panel of characterized MAbs
(6, 7,30, 41) are summarized in Fig. 3. The antigen concentra-
tions were normalized using MAb H16:J4 prior to antibody
characterization: this MAb binds a linear epitope that was
maintained in all the chimeras; thus, if one assumes that the
MAb binds similarly to each antigen, the antigenicity data
presented in Fig. 3 are relative to H16:J4 binding. All the
chimeric particles and proteins bound the antibodies specific
for the linear epitopes (H16:J4, aa 261 to 280; H16:D9, epitope
unknown; and H16:I23, aa 111 to 130). All the conformation-
ally dependent neutralizing MAbs (H16:V5, H16:E70, H16:
U4, and H16:9A) reacted with particles of chimeras ChiA-L2,
ChiE-L2, and ChiF-L2. Of the conformationally dependent
MAbs, particles of chimera ChiC-L2 recognized only H16:U4
and H16:9A, indicating the disruption of the V5 and E70
neutralizing epitopes. Particles of ChiH-L2 showed very weak
binding to conformation-dependent MAbs and strong binding
to H16:D9, which predominantly binds denatured HPV-16 L1
VLPs (7). These data indicated that the protein aggregation
products that resulted from ChiH-L2 were either unstable
and/or misassembled.
The polyclonal antiserum raised in rabbits to the L2 epitope
peptide (aa 108 to 120) bound all the chimeric particles, indi-
cating that all the HPV-16 chimeras displayed the L2 epitope.
FIG. 1. Western blot analysis of chimeric products using H16:J4
MAb. This MAb binds a linear epitope in the region aa 261 to 280. A
55-kDa product was detected for all the chimeras, similar to that of
native HPV-16 L1.
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FIG. 2. EM of chimeric particles trapped with MAb H16:J4 onto carbon-coated copper grids and negatively stained with 2% uranyl acetate (bar
 50 nm). Enlargements on the right show individual particles for ChiC-L2 and ChiE-L2, VLPs in state of disassembly for ChiF-L2, and
pentameric aggregates for ChiA-L2 and ChiH-L2.
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ChiF-L2 had the highest binding affinity, indicating that the
L2 epitope in the L1 sequence region from aa 414 to 426 is
perhaps the most highly exposed of all the constructs.
Immunization of BALB/c mice with chimeric particles and
analysis of immune sera. The results above indicated that four
of the chimeras were capable of binding one or more confor-
mation-specific neutralizing MAbs. It was important to deter-
mine if these particles could induce an HPV-16 L1 immune
response and, secondly, if the L2 epitope displayed by the
chimeras was immunogenic. Analysis of sera from mice immu-
nized with the chimeric particles indicated that there was a
strong immune response (titers  102,400) to HPV-16 L1
VLPs: end point titration data are shown in Fig. 4. Particles of
ChiE-L2 induced the strongest immune response (Fig. 4),
similar to that elicited with native HPV-16 L1 VLPs (titers 
819,200), followed by ChiF-L2 (titers  204,800) and then
ChiA-L2, ChiC-L2, and ChiH-L2, with similar end point
titers (102,400). These data correlate well with our antibody
characterization data (Fig. 3). It is interesting that the L1-
specific immune response to ChiC-L2 is much lower than that
to ChiE-L2, yet both of these assemble VLPs. We speculate
that this is due to the structural alteration of the immunodom-
inant region (V5 and E70 epitopes).
The immune response to the linear L2 epitope was analyzed
by Western blotting using the L2 protein expressed in E. coli.
The strongest response was obtained from mice immunized
with ChiF-L2 (Fig. 5). The C-terminal arm of the L1 is ex-
posed on the surface of the HPV virion, near the outer rim of
the pentamer, and is hence thought to be highly immunogenic.
ChiC-L2 and ChiE-L2 constructs had a slightly higher L2
epitope response than ChiA-L2. This correlates well with L2
antibody binding, where ChiF-L2 had the highest affinity
followed by ChiE-L2, ChiC-L2, and ChiA-L2 (Fig. 3). We
were barely able to detect the L2 epitope immune response
from ChiH-L2, suggesting that the L2 epitope was not well
presented on this chimera.
DISCUSSION
The main goal of our study was to further investigate the
potential of HPV-16 VLPs for delivery or presentation of for-
eign epitopes in a multivalent vaccine. With the data from the
crystal structure study of truncated HPV-16 L1 (10-aa N-ter-
minal deletion) (5) we were able to logically identify regions
with potential for display of foreign epitopes. Kawana et al.
(18) identified a region in the HPV-16 L2 minor capsid protein
FIG. 3. Antibody-binding characterization of the purified chimeric product using a panel of MAbs raised to HPV-16 L1 VLPs and a polyclonal
antibody raised to the L2 epitope. H16:V5 and H16:E70 are conformation-specific neutralizing MAbs, and residues Phe-50, Ala-266, and Ser-282
are critical for their binding (41). MAbs H16:U4 (binding epitope not characterized) and H16:9A (binds in the region aa 1 to 172) are both
conformation-specific and neutralizing, whereas H16:J4 (binds between aa 261 to 280) and H16:I23 (binds between aa 111 and 130) are weakly
neutralizing and recognize linear epitopes. H16:D9 has a high affinity for denatured L1.
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(aa 108 to 120) that was capable of reducing susceptibility of
the COS-1 cells to HPV-16 pseudovirion infection (19). We
chose to use this L2 epitope for incorporation into our putative
multivalent vaccine candidates.
The main factor taken into account when considering puta-
tive regions to display the L2 epitope was the preservation of
the MAb H16:V5 and MAb H16:E70 binding epitope (5, 30):
White et al. (41) mapped the binding of these neutralizing
MAbs on HPV-16 L1 VLPs to residues Phe-50, Ala-266, and
Ser-282. The H16:V5 MAb has been shown to completely
block the binding of 70% of human sera to HPV-16 virions
(30); hence, the H16:V5 binding site is considered a major
immunodominant epitope and is used as a marker for the
efficacy of HPV-16 vaccines.
Chimera ChiA-L2. The L2 epitope in ChiA-L2 is proba-
bly displayed on the outer rim of the pentamer, which puta-
tively interacts with the C-terminal arms from neighboring
pentamers. This interaction is perhaps lost in this construct, as
the cysteine at residue 175 that forms a disulfide bond with
residue 428 is replaced by a valine. Mutagenesis experiments
performed by Fligge et al. (10), Li et al. (21) and Sapp et al.
(33) have identified Cys-175 and Cys-428—both conserved
among all PV types—as being likely to form disulfide bonds.
The atomic structure model of HPV-16 L1 of Modis et al. (24)
indicates that the Cys-175 forms a disulfide bond with the
Cys-428 from an invading C-terminal arm. Therefore, the sub-
stitution of the cysteine to a valine at residue 175 could poten-
tially interfere on the formation of the interpentameric disul-
FIG. 4. End point titrations of sera from BALB/c mice immunized with chimeric products against HPV-16 L1 VLPs.
FIG. 5. Western blot analysis of immune responses to L2 epitopes presented by various chimeras. The sera were analyzed against HPV-16 L2
protein expressed in E. coli.
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fide bond, which could prevent assembly into VLPs. Based on
these data we expected chimera ChiA-L2 to form only cap-
somers, which is what we observed (Fig. 2).
Chimera ChiC-L2. ChiC-L2 the has potential of inducing
a neutralizing L1 response since it binds the neutralizing H16:
U4, H16:J4, H16:I23, and H16:9A MAbs, the last of which
targets the N terminal region of HPV-16 L1 (6). In ChiC-L2,
the L2 epitope is displayed on the head of the pentamer and
residue Tyr-135 is replaced by Thr-135 which had direct inter-
action with residue Ser-282. We believe that the Tyr-135–Ser
282 interaction is critical for H16:V5 and H16:E70 MAb bind-
ing since is Ser-282 is one of the epitopes mapped for H16V5
and H16:E70 MAb binding. There might also be other impor-
tant interactions that have been destroyed by substitution into
the D-E loop which has major interactions with the F-G loop
in HPV-16 L1 particles.
Chimera ChiE-L2 and chimera ChiF-L2. The most im-
munogenic chimera overall was ChiF-L2, where the L2 epi-
tope was presented in place of the h4 helix: this region (aa 414
to 426) is highly exposed in the atomic structure of HPV-16 L1
proposed by Modis et al. (24) and therefore probably highly
immunogenic. Chimera ChiF-L2 bound all the neutralizing
MAbs and induced a strong L1 and L2 epitope response. We
suspect that the h4 helix in native VLPs forms important in-
teractions and that altering this region prevents the formation
of VLPs. Chen et al. (4) showed that deletion of the region aa
408 to 431 resulted in pentamer formation only; these obser-
vations support our finding that ChiF-L2 is only seen to form
capsomers. Particles of ChiE-L2 would ideally be expected to
be equally immunogenic in regard to the L2 epitope as ChiF-
L2, but this is not the case. In the atomic structure of HPV-16
L1, residues 431 and 432 are less accessible due to the disulfide
bond between Cys-175 and Cys-428, and the region between
residues 433 and 443 is overall less accessible than the h4 helix
region. Therefore ChiE-L2, even though it was capable of
assembling into VLPs, induced a weak L2 response. Our anti-
body characterization data indicated that particles of ChiF-
L2 had the highest binding affinity to the L2 epitope antibody
(Fig. 3) and that these particles induced a strong L1 immune
response (titers  204,800) in BALB/c mice, though this was
lower than that of ChiE-L2 (819,200). The stronger L1
immune response induced by particles of ChiE-L2 could be
attributed to the formation of VLPs, which are probably more
immunogenic than capsomers.
Chimera ChiH-L2. The low binding affinity of conforma-
tion-specific MAbs to particles of ChiH-L2 could be attrib-
uted to the alteration of the L1 structure by the substitution of
the L2 epitope into the C-D loop. The C-D loop (residues 79
to 94) forms important contacts between subunits in pentava-
lent pentamers and adjacent subunits in hexavalent pentamers
(24): the C-D loop from one pentamer interacts directly with
the C-D loop from a neighboring pentamer in an opposing
manner. The C-D loop is highly conserved among PV types;
hence, we speculate that substitution of the L2 epitope in the
C-D loop (ChiH-L2) could have potentially prevented the
formation of VLPs. The EM results, which showed that the
products of chimera ChiH-L2 are predominately capsomers,
support the notion of a change in the conformation of the L1
tertiary structure.
EM of chimeric particles. Electron microscopy (EM) of
chimeric L1 protein aggregates purified by isopycnic CsCl gra-
dient fractionation from recombinant baculovirus-infected in-
sect cells indicated that ChiC-L2 and ChiE-L2 appeared to
retain the ability to assemble into recognizable VLPs as well as
capsomers, while the other three only formed capsomers and
irregular aggregates (Fig. 2). This indicates that substitutions
of the L2 peptide sequence in the D-E loop, which is located
on the pentamer head and C-terminal arm (region between the
h4 helix and the 	-J sheet), are better tolerated structurally
than the other substitutions in terms of complete assembly but
that none of the substitutions affected the first-stage pentam-
eric capsomer assembly. Substitution in the D-E loop does not
affect the gross structure, but only the region around the F-G
loop; hence, the loss in binding to MAb H16:V5 and H16:E70.
The EM results also indicate that the sequence in the C-D loop
is critical for maintaining the integrity of PV particles. The
destruction of the h4 helix might have resulted in a gross
conformation change in the packing of the C-terminal arm
from a neighboring subunit preventing VLP assembly.
In summary, we have successfully investigated the use of
HPV-16 L1 to present the HPV-16 L2 epitope (LVEETSFID
AGAP) (18), which cross-neutralizes HPV-6 and -16 (16). Of
all the chimeras tested we found chimera ChiF-L2 (substitu-
tion into the h4 helix region; aa 414 to 426) to be the most
effective at both presenting the L2 epitope and maintaining the
neutralizing MAb H16:V5 and H16:E70 binding. H16:V5
MAbs have been shown to block more than 70% of (HPV-16-
infected) patient sera from binding HPV-16 pseudovirions
(30), thus maintaining the V5 epitope is seen as critical for
eliciting a neutralizing HPV-16 response.
Further, recent studies have shown that sera raised to two
linear epitopes on HPV-16 were capable of neutralizing HPV-
16, -18, -31, -33, -45, -55, and -59 (9). All of our chimeras bind
MAbs raised against these two epitopes. Therefore, our inves-
tigation into the use of PV to display foreign epitopes opens
avenues for the synthesis of novel multivalent vaccines, where
the epitopes could be displayed in a variety of regions, and
multiple epitopes could also potentially be displayed on the
particle at different surface locations.
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